Stereotactic Ablative Radiotherapy and T Cell Biodistribution for Oligoprogressive Head and Neck Cancer (START-HN)

ACTRN 12622000495729

Brief Summary

The purpose of this study is to compare the immune responses within cancer tumours which have and have not been treated with stereotactic ablative body radiotherapy (SBRT).

Intervention/Treatment

• Stereotactic ablative radiotherapy (SBRT).

Inclusion Criteria

1. Head and neck SCC with oligo-progression to 1-10 extracranial lesions, lesion size no more than 5cm and involving no more than 3 organs.
2. Sites of oligo-progressive disease can be targetable with SBRT and safely treated.
3. At least one tumour lesion can be observed and will not be in the beam path of SBRT, and the observed lesion must be measurable by the criteria of RECIST version 1.1.